PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock.
Holger Thiele, Ibrahim Akin, Marcus Sandri...
https://pubmed.ncbi.nlm.nih.gov/29083953/Actively Recruiting
Led by Leipzig Heart Science gGmbH · Updated on 2026-10-27
50
Participants Needed
1
Research Sites
4 weeks
Total Duration
Cardiogenic shock following an acute myocardial infarction is linked to high short-term death rates despite current treatments. This condition causes a strong inflammatory response, with elevated C-reactive protein CRP believed to worsen heart damage and organ problems. Researchers are studying whether removing CRP from the blood can improve outcomes in these patients. This trial compares standard care alone to standard care plus selective CRP removal through a procedure called CRP apheresis using the PentraSorb4-CRP device. Participants receiving CRP apheresis undergo up to three sessions starting within about 5 hours after randomization, with additional sessions at approximately 30 and 54 hours. The study is a randomized, open-label pilot across multiple centers. Participants are closely monitored with repeated assessments of the CLIP score, a measure of risk, at around 66 hours after randomization and earlier timepoints. Other outcomes include death rates, heart and kidney function markers, inflammatory biomarkers, and safety events like bleeding or infection. The study runs until about 30 days post-treatment, with data collection continuing until October 2027.
CONDITIONS
CRP Apheresis in Infarct-Related Cardiogenic Shock
C
CRP-SHOCK Leipzig Heart Science gGmbH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Leipzig Heart Science gGmbH
Lead Sponsor
Helios Health Institute GmbH
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 days
Participants receive either standard care alone or standard care plus selective CRP apheresis using the PentraSorb4-CRP system. CRP apheresis is started within about 5 hours after randomization and repeated at approximately 30 and 54 hours.
3 treatment sessions
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Holger Thiele, Ibrahim Akin, Marcus Sandri...
https://pubmed.ncbi.nlm.nih.gov/29083953/Holger Thiele, Uwe Zeymer, Franz-Josef Neumann...
https://pubmed.ncbi.nlm.nih.gov/22920912/Leipzig Heart Science gGmbH
Lead Sponsor
Helios Health Institute GmbH
Collaborating Sponsor